When you talk to a number of people who have ever consumed magic mushrooms and other plant-based psychedelic substances, you will inevitably encounter stories of “bad trips” characterized by feelings of entrapment, mild anxiety, terror, alienation and other such unpleasant effects. The risk of these “bad trips” scares a lot of people away from using psychedelics, and one psychedelic medicine company has come up with an invention that could neutralize and stop a bad LSD trip in its tracks.
Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”), together with the Liechti Laboratory found at Basel University Hospital in Switzerland, are the entities behind the invention which has the ability to shorten or stop a bad LSD trip once it is noticed.
Switzerland has marked itself out as very important on matters of psychedelic research, building on the synthesis of LSD decades ago in that country.
MindMed says that its new product has the ability to halt the hallucinogenic effects of psychedelic drugs, such as LSD. This means that rather than terminate a psychedelic-assisted therapy session due to the bad trip, the session can continue once the neutralizer takes care of the bad experience that a patient is having.
It should be remembered that most of the psychedelic medicines being developed have to be administered in a controlled clinical setting, so the professional in charge of the patient’s treatment can detect when the patient exhibits signs of a bad trip and the neutralizer can be given to bring the situation back to the desired level.
The research on the LSD neutralizer is still in its infancy, but the results so far registered have given MindMed and its partners enough encouragement to file for a worldwide patent on the treatment. The patent application was filed in the U.S. and is being considered.
MindMed has its sights set on a lot more technologies within the psychedelic medicine space, and they believe they will file for and acquire a lot more patents in this emerging industry.
The invention of the bad trip neutralizer couldn’t have come at better time. Bad trips are scary, and it is great to have a solution to this problem available long before psychedelics are widely used to manage mental and physical health challenges. Since people react differently to medicine, it is comforting when prospective patients know that their healthcare provider has a solution at hand in case the patient is one of those few who experience a bad trip when they are given a psychedelic substance.
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.